SCHEMBL114063

SCHEMBL114063

CC(Cc1ccc(-c2ccccc2)cc1)OC(N)=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.55
PSAT1 Q9Y617 2/20 0.55
PPARG P37231 8/20 0.50
PPARA Q07869 6/20 0.50
MME P08473 4/20 0.49
ACE P12821 4/20 0.49
CPA1 P15085 2/20 0.49
ACE2 Q9BYF1 2/20 0.49
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
FFAR1 O14842 1/20 0.47
ACACB O00763 1/20 0.47
ABCC4 O15439 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
PTGS1 P23219 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28237997 0.90 SLC6A2 (0.50) SRRTSHRPTGS1
SCHEMBL1811694 0.90 SLC6A2 (0.50) SRRTSHRPTGS1
SCHEMBL28914994 0.90 SLC6A2 (0.50) SRRTSHRPTGS1
SCHEMBL8716757 0.85 MMP12 (0.56) SRRPSAT1PPARGPPARAMME
SCHEMBL22474260 0.84 SRR (0.53) SRRPSAT1PPARGPPARAMME
SCHEMBL2747604 0.83 TAAR1 (0.53) LMNATSHR
SCHEMBL2561209 0.83 NPC1 (0.45) LMNATSHRPTGS1
SCHEMBL9136582 0.83 PPARG (0.44) PPARGPPARAFFAR1ACACBLMNA
SCHEMBL2747602 0.83 TAAR1 (0.53) LMNATSHR
SCHEMBL113258 0.83 PPARA (0.44) PPARGPPARALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008013427-A1 ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME LG CHEM, LTD. (KR) 2008-01-31 WO claimed
WO-2007056455-A2 N-PROTECTED AMINOINDANES AND METHODS OF THEIR PREPARATION TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-05-18 WO claimed
WO-2026107134-A1 USE OF SMALL MOLECULE GLUTAMINASE INHIBITORS FOR TREATING AGE-RELATED DISORDERS LEAL THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
EP-4724418-A1 TRICINE AND CITRIC ACID-BASED CATIONIC LIPIDS Sanofi (FR) 2026-04-15 EP disclosed
WO-2025151874-A1 INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-07-17 WO disclosed
WO-2025104706-A2 SMALL MOLECULE MODULATORS OF MAS AND MRGD RECEPTORS XITRA THERAPEUTICS GMBH (DE) 2025-05-22 WO disclosed
EP-4554671-A1 CYCLIC PEPTIDE INHIBITORS OF IL-23 JANSSEN Pharmaceutica NV (BE) 2025-05-21 EP disclosed
EP-4486336-A2 CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-01-08 EP disclosed
WO-2025003759-A1 DIANHYDROHEXITOL BASED IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY SANOFI (FR) 2025-01-02 WO disclosed
EP-4475837-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2024-12-18 EP disclosed
US-12054570-B2 Functional oligomers and functional polymers including hydroxylated polymers and conjugates thereof and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-08-06 US disclosed
EP-0730570-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1996-09-11 EP disclosed
WO-1996022275-A1 METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES G.D. SEARLE & CO. (US) 1996-07-25 WO disclosed
WO-1996011943-A1 NEW PEPTIDES WITH IMMUNOMODULATORY EFFECTS ASTRA AKTIEBOLAG (SE) 1996-04-25 WO disclosed
US-5506355-A REACTING DIAMINE HAVING DIOL PROTECTED WITH CYCLIC ACETAL GROUP IN SOLVENT WITH HINDERED AMINE BASE AND SULFONYL GROUP PRECURSOR, ALKYLATING IN PRESENCE OF BASE THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-04-09 US disclosed
EP-0651761-A1 METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES BIONEBRASKA, INC. (US) 1995-05-10 EP disclosed
WO-1994001451-A2 METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES BIONEBRASKA, INC. (US) 1994-01-20 WO disclosed
EP-0222889-A4 CYTIDINE ANALOGS. INTEGRATED GENETICS INC (US) 1988-09-28 EP disclosed
EP-0222889-A1 CYTIDINE ANALOGS. INTEGRATED GENETICS INC (US) 1987-05-27 EP disclosed
WO-1986006726-A1 CYTIDINE ANALOGS INTEGRATED GENETICS, INC. (US) 1986-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054570-B2 Functional oligomers and functional polymers including hydroxylated polymers and conjugates thereof and uses thereof PUF60, PGLS, PARG SRR 2941/4885PSAT1 920/4885PPARG 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.